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Edited by Veli-Pekka LehtoAbstract Multi drug resistance (MDR) is deﬁned as the ability
of tumor cells to become resistant to unrelated drugs. Tyrosine
kinase inhibitor imatinib has been demonstrated to be eﬀective
in the treatment of certain tumors. In particular, imatinib inhib-
its Bcr-Abl kinase activity, c-kit and the phosphorylation of
platelet-derived growth factor (PDGF) receptors. In this work,
we show that imatinib inhibits PDGF phosphorylation not only
in wt Kaposi sarcoma (KS) but also in multi drug resistant KS
cells. This was associated with an increased apoptosis in wt cells
and an increased autophagy in MDR-KS cells. These data add
new insights to the possible use of imatinib in the overcoming
of MDR in KS cells.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Receptor tyrosine kinases have been proposed as potential
targets for antitumor therapy. Imatinib mesylate (also known
as STI571 or Gleevec, and hereafter called imatinib) belongs
to the group of new drugs classiﬁed as signal transduction
inhibitors and has been approved as an eﬀective treatment
for Chronic Myeloid Leukaemia [1]. Imatinib inhibits Bcr-
Abl kinase activity, causing apoptosis in Philadelphia+ cells
and inducing cytogenetic remissions in the majority of CML
patients [1]. Additional tyrosine kinases are inhibited by imati-
nib: c-kit, the receptor for kit ligand (KL) and the two struc-
turally similar platelet-derived growth factor receptors
(PDGFRs), PDGFR-a and PDGFR-b [1,2]. Results of recent
clinical studies have shown that imatinib therapy is well
tolerated and leads to remission in patients with c-kit-positiveAbbreviations: KS, Kaposi sarcoma; MDR, multi drug resistance;
DOX, Doxorubicin; PDGFRs platelet-derived growth factor recep-
tors; KL, kit ligand
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function mutations in c-kit [3]. Imatinib has also been reported
to inhibit the growth of several tumors, including Kaposi sar-
coma (KS), all of which may express the PDGF/PDGFR or
KL/c-kit autocrine growth loops [4–11]. Kaposis sarcoma is
a multi-focal angioproliferative disease that occurs in HIV-in-
fected patients and is a leading cause of mortality and morbid-
ity in the acquired immune deﬁciency syndrome (AIDS) [12]. A
number of cytokines and growth factors have been implicated
in KS progression [13,4]. In particular, activation of PDGF
and c-kit receptors has been proposed to play a role in mediat-
ing the growth of AIDS-related KS [4]. Furthermore,
although a reduced incidence and regression of KS have been
reported in AIDS patients treated with antiretroviral therapies
or with chemotherapy (e.g. by Doxorubicin), the drug toxicity
and the appearance of multi drug resistance (MDR) represent
the main cause of therapeutic failure. Here, we show that
imatinib mainly induces apoptosis in KS cells and, more inter-
estingly, autophagy in MDR-KS cells.2. Materials and methods
2.1. Cells culture and treatments
The wild type Kaposis sarcoma cell line (wt-SLK) and doxorubicin
(DOX) resistant MDR+ cells (SLK–DOX) were kindly provided by
Dr. BM Lucia and Prof. R. Cauda (Catholic University, Rome, Italy).
The cells were grown in RPMI-1640 supplemented with 10% FCS,
2 mM glutamine and antibiotics. SLK–DOX cells were selected from
the original wt-SLK cell line by exposure to 50 ng/ml of the drug. Drug
resistance was maintained by adding relevant concentrations of the
drug every 4 weeks. Cells were cultured in drug-free medium for at
least ten days before experimental procedures. Degrees of resistance
were assessed in terms of MTT assay [14] and the P-gp and/or MRP
function [15]. Cells were treated with imatinib (Novartis) at diﬀerent
concentrations (15, 25 and 35 lM) in the growth medium at 37 C in
a 5% CO2 atmosphere for 48 h.
2.2. Cell growth
Cell proliferation was analyzed by performing growth curves both in
wt-SLK and SLK–DOX cells. Cell number was determined by count-
ing cells daily using the trypan blue (GIBCO, Loughbolough, UK)
exclusion test.
2.3. Analytical cytology
For static and ﬂow cytometry analyses, control and treated cells
were ﬁxed with 4% paraformaldehyde in phosphate-buﬀered saline
(PBS) for 30 min at room temperature. After washing in the sameation of European Biochemical Societies.
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Chemical Co., St. Louis, MO, USA) in PBS for 5 min. For PDGFR-
b (phosphorylated and non-phosphorylated) monoclonal antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) directed against
these antigens were used. For Bcl-2 and Beclin-1 (Santa Cruz Biotech-
nology) polyclonal antibody directed against these antigens were used.
After 30 min at 37 C, cells were washed and then incubated with an
anti-mouse ﬂuorescein-linked or anti-rabbit ﬂuorescein-linked whole
antibodies (Sigma). For apoptosis detection the nuclei were stained
with Hoechst 33258 (Sigma) at 37 C for 15 min. For a qualitative
analysis all samples were mounted on glass cover-slips with glycerol–
PBS (2:1) and analyzed by intensiﬁed video microscopy (IVM)
with a Nikon Microphot ﬂuorescence microscope equipped with a
Zeiss CCD camera. Regarding ﬂow cytometry analyses, all the samples
were recorded with a FACScan ﬂow cytometer (Becton–Dickinson,
Mountain View, CA, USA) equipped with a 488 nm argon laser. At
least 20000 events have been acquired. The median values of ﬂuores-
cence intensity histograms were used to provide a semi-quantitative
analysis.Fig. 1. Quantitative analysis of non-phosphorylated and phosphorylated PD
Western blotting (A). Flow cytometry evaluation of phosphorylated and n
results (left panels) or as mean histograms (right panel, mean values ± S.D. fr
was used.2.4. Acid compartment detection
Autophagic vacuoles were labelled with the autoﬂuorescent drug,
monodansylcadaverine (MDC, Sigma), by incubating cells with
0.05 mM MDC in phosphate-buﬀered saline (PBS) at 37 C for
10 min. Acid compartments were also labelled by incubating the cells
with 1 lM LysoTracker (LTR, Molecular Probes, Eugene, OR,
USA) in the culture medium at 37 C for 15 min. Cells were then ﬁxed
with 4% paraformaldehyde (w/v in PBS) for 1 h at room temperature
(25 C). Cells were analyzed by IVM.
Regarding ﬂow cytometry analyses, all the samples were evaluated
with a FACScan ﬂow cytometer (Becton–Dickinson) equipped with
a 488 nm argon laser. At least 20000 events have been acquired. The
median values of ﬂuorescence intensity histograms were used to pro-
vide a semi-quantitative analysis.
2.5. Morphometric analyses
Quantitative evaluation of apoptotic cells was performed counting
at least 300 cells at high magniﬁcation (500·) at the ﬂuorescence micro-
scope after Hoechst labeling.GF receptors (a and b) and c-kit in both wt and resistant SLK cells by
on-phosphorylated PDGF receptors is shown in (B) as representative
om four independent experiments). Students t-test to correlate samples
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Activation state of the caspase 8, 9 and 3 was evaluated by using the
CaspGLOW ﬂuorescein active caspase staining Kit (MBL, Woburn,
MA, USA). This kit provides a sensitive means for detecting activated
caspases in living cells. The assay utilizes speciﬁc caspases inhibitors
(IETD-FMK for caspase 8, LEHD-FMK for caspase 9 and DEVD-
FMK for caspase 3) conjugated to FITC as the ﬂuorescent marker.
These inhibitors are cell permeant, non-toxic and irreversibly bind to
caspase active form. The FITC label allows detection of activated casp-
ases in apoptotic cells directly by ﬂow cytometry. Cells were incubated
with FITC-IETD-FMK, FITC-LEHD-FMK or FITC-DEVD-FMK
for 1 h at 37 C following manufacturer instruction. After this time
samples were washed three times and immediately analyzed on a
cytometer by using FL-1 channel. Two additional experimental con-Fig. 2. (A) Morphometric analysis indicating the percentage of apoptotic ce
imatinib for 48 h. Mean values from four independent experiments ± S.D. are
of imatinib concentration. (B) Fluorescence microscopy of wt and resistant SL
occurred in both cell lines 48 h after imatinib exposure (right panels).trols were also considered: (i) samples prepared by pre-treating cells
with speciﬁc inhibitors of caspase 8, 9 or 3 and (ii) unlabelled cells (neg-
ative control)2.7. Western blotting
To study the eﬀect on the phosphorylation of PDGFR-a and
PDGFR-b, subconﬂuent cells shifted to 0.1% FBS overnight, were cul-
tured with and without 15 lmol/l imatinib for 4 h followed by an addi-
tional 10 min of incubation in the absence or in the presence of 10 ng/
ml human recombinant PDGF-BB (Roche, Welwyn Garden City,
UK). At the end of incubation, cells were washed with PBS, harvested
and cells pellet was lysed in the ice-cold radioimmunoprecipitation as-
say (RIPA) buﬀer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mMlls in wt and resistant SLK cells exposed to diﬀerent concentrations of
shown. Note as percentage of apoptotic cells increases with increasing
K stained with Hoechst 33258. Note that the chromatin condensation
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PMSF, 1 mg/ml leupeptin, 1 mg/ml aprotinin plus 1% Triton X-100),
followed by centrifugation at 14000 rpm at 4 C for 20 min. Protein
concentration was determined using the Bradford protein assay meth-
od. Equal amounts (80 lg) of sample protein were loaded onto 7%
SDS–polyacrylamide gels and then electrotransferred onto nitrocellu-
lose membranes which were incubated with 1:300 dilution of the fol-
lowing primary antibodies: aﬃnity-puriﬁed polyclonal rabbit anti-
phospho-PDGFR-a (anti-p-PDGFR-a), anti-phospho-PDGFR-b
(anti-p-PDGFR-b) and monoclonal mouse anti-actin (Santa Cruz Bio-
technology). Membranes were then incubated with the horseradish
peroxidase-conjugated secondary antibodies (1:10000 dilution; Santa
Cruz Biotechnology). Detection was performed using enhanced chemi-
luminescence (ECL, Amersham Life Science, Arlington Heights, IL).
Secondary antibodies alone served as negative controls. Protein bands
were quantiﬁed by densitometric analysis using a densitometry com-
puter software (Kodak Digital Science, NY).
2.8. Statistical analyses
Cytoﬂuorimetric results were statistically analyzed by using the
parametric Kolmogorov–Smirnov test using Cell Quest Software.
Morphometric data (reported as mean ± standard deviation, S.D.Fig. 3. (A) Cell proliferation is inhibited by treatment with imatinib 15 lM in
by ﬂow cytometry. Note the higher expression of this molecule in wt cells with
of this protein was signiﬁcantly decreased 24 and 48 h after imatinib expos
experiments. Students t-test to correlate samples was used (*P < 0.01). (C, D)
in both wt and SLK–DOX cells. Note that, especially in SLK–DOX cells, the
mean values ± S.D. from four independent experiments. Students t-test to cfrom at least four separate experiments) were analyzed by using Stu-
dent t-test. Only P < 0.05 was considered as signiﬁcant.3. Results and discussion
3.1. PDGFR expression
We ﬁrst examined non-phosphorylated and phosphorylated
PDGFR-b, PDGFR-a and c-kit expression in both wt and
resistant SLK cells by Western blotting and ﬂow cytometry.
As shown in Fig. 1A, both wt-SLK and SLK–DOX cells ex-
pressed the PDGF receptors, whilst c-kit was barely detect-
able. Ligand-induced phosphorylation of PDGFR-b,
PDGFR-a and c-kit was inhibited to background levels in cells
treated with imatinib without aﬀecting the expression levels of
the receptors. A high expression of b-subtype non-phosphory-
lated receptor as detected by ﬂow cytometry is also shown in
Fig. 1B. Since it was suggested that inhibition of PDGFR
phosphorylation is associated with apoptosis induction [16],both wt and SLK–DOX cells. (B) Quantitative analysis of Bcl-2 protein
respect to MDR+ cells. Also note that in both cell lines the expression
ure. Data are reported as mean values ± S.D. from four independent
Activation state of caspase 9 (C) and 3 (D) evaluated by ﬂow cytometry
se caspases are activated signiﬁcantly by imatinib. Data are reported as
orrelate samples was used (*P < 0.01).
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duced apoptosis and the mechanism involved.
3.2. Apoptosis and cell growth evaluation
In order to verify if imatinib could induce apoptosis, we ex-
posed both SLK cell lines to diﬀerent concentrations of imati-
nib (15, 25, 35 lM for 48 h). As shown in Fig. 2A, imatinibFig. 4. (A) IVM analysis showing the presence of diﬀuse lysosomal vacuole
vacuoles obtained by ﬂow cytometry from four independent experiments.
treatment in SLK–DOX cells (right). (B) Quantitative evaluation of Beclin1 e
(right) obtained from four independent experiments ± S.D. In ordinate, media
was used (*P < 0.01).was able to induce apoptosis in a dose dependent manner in
both cell lines. In Fig. 2B the typical sign of apoptosis, i.e.
chromatin condensation, is shown. Moreover, considering that
the plasma steady state levels of imatinib observed in treated
patients correspond to values between 3 and 10 lM [17], we fo-
cused our attention on the eﬀects induced by imatinib at 15 lM
on both wt and resistant SLK cells. In particular, as reporteds in cells exposed to imatinib (left). Quantitative analysis of lysosomal
Note the signiﬁcantly increased lysosome acidiﬁcation after imatinib
xpression in a representative experiment (left). Mean values histograms
n ﬂuorescence intensity is reported. Students t-test to correlate samples
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after 15 lM imatinib exposure in both wt and SLK–DOX cells.
Hence, imatinib was capable of impairing cell growth and to
induce apoptosis in both wt and MDR-KS cells.
3.3. Bcl-2 expression
We then analyzed the expression of Bcl-2, an integral mem-
brane protein mainly located on the outer membrane of mito-
chondria. Its overexpression prevents cells from undergoing
apoptosis in response to a variety of stimuli [18]. In our exper-
iments, a quantiﬁcation of this protein was carried out in both
wt and resistant SLK cells. As shown in Fig. 3B, the expression
of this protein decreased signiﬁcantly 24 and 48 h after imati-
nib treatment in both cell lines.
3.4. Caspase activity
Apoptosis occurs through two main pathways. The ﬁrst, re-
ferred to as the extrinsic or cytoplasmic pathway, is triggered
through the death receptors. The second is the intrinsic or
mitochondrial pathway that, when stimulated, leads to the re-
lease of cytochrome c from the mitochondria and the activa-
tion of death signals. Both pathways involve the activation
of a cascade of proteases called caspases that cleave regulatory
and structural molecules, culminating in the death of the cell.
Considering that intrinsic and extrinsic pathways converge to
caspase 3 by caspase 8 (in the extrinsic pathway) and by cas-
pase 9 (in the intrinsic pathway) we evaluated the activation
state of these proteases in both wt and SLK–DOX cells. Data
shown in Fig. 3 indicate that imatinib was able to induce apop-
tosis by activating caspase 9 (Fig. 3C) and 3 (Fig. 3D). Inter-
estingly, imatinib-induced caspase activation was signiﬁcantly
higher in SLK–DOX cells with respect to wt cells. No diﬀer-
ences were detected in the activation state of caspase 8 (data
not shown). This may suggest that mitochondrial pathway
could play a key role in imatinib-induced cell death.
3.5. Imatinib and lysosomal function
Autophagy is an archetypical cellular degradation mecha-
nism in which an increase of lysosomal compartment and the
formation of autophagic vacuoles can be detected [19]. It has
recently been suggested that imatinib is capable of inducing
autophagy and that this might represent an additional mecha-
nism leading to growth arrest, apoptosis and tumor regression
[20]. To determine whether imatinib modulated endolysosomal
compartment in KS cells, a speciﬁc lysosomal marker, the lyso-
tracker, was used. This probe allowed us to investigate the
alteration of lysosomal function, i.e. the acidiﬁcation of lyso-
somes and or their traﬃcking in cells. Analyses conducted by
ﬂuorescence microscopy revealed the presence of diﬀuse lyso-
somal vesicles in cells exposed to imatinib with respect to un-
treated cells (Fig. 4A). Quantitative evaluations, obtained by
ﬂow cytometry analyses, emphasized an increased lysosome
acidiﬁcation after imatinib treatment. Importantly, this in-
crease was much more evident in MDR-KS cells, i.e. in
SLK–DOX cells (Fig. 4A). Similar results were obtained by
using monodansylcadaverine, an autophagosomal marker
(data not shown). Finally, these results were conﬁrmed by
the analysis of Beclin-1/ATG6 [21].
The results obtained emphasized a link between apoptosis
and autophagy induced by imatinib. Autophagy induction
could be considered as an additional mechanism of imatinibto induce growth arrest and promote cell death in sarcoma
cells. Moreover, considering that resistance to chemotherapeu-
tic agents predominantly occurs through defects in the apopto-
tic signaling pathway [22], the identiﬁcation of agents, such
imatinib, that can stimulate autophagy may become of interest
in the clinical management of Kaposis sarcoma. In fact, the
possibility that the inhibition of PDGFR phosphorylation by
imatinib could trigger a series of cellular pathways leading to
cell demise by apoposis (in wt cells) or inducing autophagy
(in MDR+ cells) can also open new therapeutic strategies,
e.g. in terms of combinatory drug therapies.
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